|
[1] GINES P,SOLAE,ANGELI P,et al. Hepatorenal syndrome[J]. Nat Rev Dis Primers,2018,4(1):23.
|
|
[2] ANGELI P,GINES P,WONG F,et al. Diagnosis and management of acute kidney injury in patients with cirrhosis:Revised consensus recommendations of the International Club of Ascites[J]. J Hepatol,2015,62(4):968-974.
|
|
[3] RESTUCCIA T,ORTEGA R,GUEVARA M,et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study[J]. J Hepatol,2004,40(1):140-146.
|
|
[4] MEOLA M,NALESSO F,PETRUCCI I,et al. Clinical scenarios in acute kidney injury:Hepatorenal syndrome[J]. Contrib Nephrol,2016,188:33-38.
|
|
[5] LEITHEAD JA,HAYES PC,FERGUSON JW. Review article:Advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction[J]. Aliment Pharmacol Ther,2014,39(7):699-711.
|
|
[6] WIEST R,LAWSON M,GEUKING M. Pathological bacterial translocation in liver cirrhosis[J]. J Hepatol,2014,60(1):197-209.
|
|
[7] MANDORFER M,HECKING M. The renaissance of cholemic nephropathy:A likely underestimated cause of renal dysfunction in liver disease[J]. Hepatology,2019,69(5):1858-1860.
|
|
[8] GLASS L,SHARMA P. Evidence-based therapeutic options for hepatorenal syndrome[J]. Gastroenterology,2016,150(4):1031-1033.
|
|
[9] KIM HY,CHO EJ,CHUN S,et al. Red blood cell alloimmunization in korean patients with myelodysplastic syndrome and liver cirrhosis[J]. Ann Lab Med,2019,39(2):218-222.
|
|
[10] SANYAL AJ,BOYER T,GARCIA-TSAO G,et al. A randomized,prospective,double-blind,placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome[J]. Gastroenterology,2008,134(5):1360-1368.
|
|
[11] GLUUD LL,CHRISTENSEN K,CHRISTENSEN E,et al. Terlipressin for hepatorenal syndrome[J]. Cochrane Database Syst Rev,2012,(9):CD005162.
|
|
[12] GIFFORD FJ,MORLING JR,FALLOWFIELD JA. Systematic review with meta-analysis:Vasoactive drugs for the treatment of hepatorenal syndrome type 1[J]. Aliment Pharmacol Ther,2017,45(5):593-603.
|
|
[13] ISRAELSEN M,KRAG A,ALLEGRETTI AS,et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome[J].Cochrane Database Syst Rev,2017,9(9):CD011532.
|
|
[14] NGUYEN-TAT M,JAGER J,REY JW,et al. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2[J]. United European Gastroenterol J,2019,7(4):529-537.
|
|
[15] SINGH V,GHOSH S,SINGH B,et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome:A randomized study[J]. J Hepatol,2012,56(6):1293-1298.
|
|
[16] QIN YX,LONG FL,MAO DW,et al. Efficacy and safety of norepinephrine combined with albumin versus terlipressin combined with albumin in treatment of type 1 hepatorenal syndrome:A Meta-analysis[J]. J Clin Hepatol,2019,35(10):2266-2271.(in Chinese)覃艳新，龙富立，毛德文，等．去甲肾上腺素或特利加压素联合白蛋白治疗1型肝肾综合征效果及安全性比较的Meta分析[J]．临床肝胆病杂志，2019,35(10):2266-2271.
|
|
[17] ZIRONI G,ROSSI C,SIRINGO S,et al. Short-and longterm hemodynamic response to octreotide in portal hypertensive patients:A double-blind,controlled study[J]. Liver,1996,16(4):225-234.
|
|
[18] CAVALLIN M,KAMATH PS,MERLI M,et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome:A randomized trial[J].Hepatology,2015,62(2):567-574.
|
|
[19] WANG L,LONG Y,LI KX,et al. Pharmacological treatment of hepatorenal syndrome:A network meta-analysis[J]. Gastroenterol Rep(Oxf),2020,8(2):111-118.
|
|
[20] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]J Hepatol,2018,69(2):406-460.
|
|
[21] SRIVASTAVA S,SHALIMAR,VISHNUBHATLA S,et al. Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine,furosemide,and albumin in hepatorenal syndrome[J]. J Clin Exp Hepatol,2015,5(4):276-285.
|
|
[22] SCHRIER RW,GROSS P,GHEORGHIADE M,et al. Tolvaptan,a selective oral vasopressin V2-receptor antagonist,for hyponatremia[J]. N Engl J Med,2006,355(20):2099-2112.
|
|
[23] PIAO LS. Clinical effect of tolvaptan combined with albumin in treatment of liver cirrhosis patients with type 2 hepatorenal syndrome[J]. Guide China Med,2015,13(25):150.(in Chinese)朴莲淑．托伐普坦联合白蛋白治疗肝硬化合并2型肝肾综合征的疗效观察[J]．中国医药指南，2015,13(25):150.
|
|
[24] HIRAMINE Y,UTO H,MAWATARI S,et al. Effect of tolvaptan on the prognosis of patients with hepatic ascites[J]. Hepatol Res,2019,49(7):765-777.
|
|
[25] SNOWDON VK,LACHLAN NJ,HOY AM,et al. Serelaxin as a potential treatment for renal dysfunction in cirrhosis:Preclinical evaluation and results of a randomized phase 2 trial[J]. PLo S Med,2017,14(2):e1002248.
|
|
[26] DE BK,GANGOPADHYAY S,DUTTA D,et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis:A randomized controlled trial[J]. World J Gastroenterol,2009,15(13):1613-1619.
|
DownLoad: